Cargando…

Adalimumab in the treatment of arthritis

Tumor necrosis factor (TNF) has been implicated in a number of arthritic disease states, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab is the first fully human, high-affinity, recombinant immunoglobulin G(1) (IgG(1)) anti-TNF monoclonal antibody. Adalimu...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mease, Philip J
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936294/ https://www.ncbi.nlm.nih.gov/pubmed/18360621

Ejemplares similares

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
por: Mease, Philip J.
Publicado: (2011)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management
por: Mease, Philip
Publicado: (2020)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Successful Treatment of Pseudoseptic Arthritis Contained Massive Purulent Fluid with Adalimumab in Rheumatoid Arthritis
por: Chung, Chong Hyuk, et al.
Publicado: (2020)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
por: García-De-Vicuña, Carmen, et al.
Publicado: (2013)

Profile of adalimumab and its potential in the treatment of uveitis
por: Balevic, Stephen J, et al.
Publicado: (2016)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Preface to the psoriatic arthritis supplement
por: Mease, Philip
Publicado: (2020)

Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
por: Marzan, Katherine Anne B
Publicado: (2012)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
por: Kotaniemi, Kaisu, et al.
Publicado: (2011)

Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis
por: Bergström, Ulf, et al.
Publicado: (2018)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
por: Van den Bosch, Filip, et al.
Publicado: (2018)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
por: Nguyen, Dao X., et al.
Publicado: (2018)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Long-term use of adalimumab in the treatment of rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2009)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2gul10qjk825jb7jmol9gdbm2r